| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)NCT04439071 | PTC Therapeutics | Phase 2, Phase 3 | Terminated | 2022-07-20Actual |
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022 | KPTI | Phase 2, Phase 3 | Active not recruiting | 2026-12Estimated |
| Crossover Trial of AD036 in Obstructive Sleep ApneaNCT04445688 | Apnimed | Phase 2 | Completed | 2020-12-01Actual |
| Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisNCT04445987 | ARQT | Phase 2 | Completed | 2022-11-19Actual |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 | Exelixis | Phase 3 | Active not recruiting | 2024-04-19Actual |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationNCT04447469 | KNSA | Phase 2, Phase 3 | Completed | 2021-11-12Actual |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinNCT04452591 | CGON | Phase 3 | Active not recruiting | 2030-06-16Estimated |
| Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainNCT04455633 | Lexicon Pharmaceuticals | Phase 2 | Completed | 2022-05-23Actual |
| A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAHNCT04457336 | Spruce Biosciences | Phase 2 | Terminated | 2024-02-09Actual |
| A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract CancersNCT04466891 | Jazz Pharmaceuticals | Phase 2 | Completed | 2023-07-28Actual |
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaNCT04467840 | RedHill Biopharma Limited | Phase 2, Phase 3 | Completed | 2021-07-18Actual |
| Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisNCT04475432 | TARS | Phase 2, Phase 3 | Completed | 2021-05-04Actual |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)NCT04476017 | SUPN | Phase 2 | Completed | 2022-03-25Actual |
| Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)NCT04480840 | PLRX | Phase 2 | Completed | 2024-02-26Actual |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresNCT04485104 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2025-01-28Actual |
| ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04488419 | LeonaBio | Phase 2, Phase 3 | Completed | 2024-07-15Actual |
| A Study of ATH-1017 in Mild to Moderate Alzheimer's DiseaseNCT04491006 | LeonaBio | Phase 2 | Completed | 2022-05-20Actual |
| Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBMNCT04492163 | NovoCure GmbH | Phase 2 | Completed | 2023-06-20Actual |
| CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153 | CADL | Phase 2 | Active not recruiting | 2024-12-31Actual |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLNCT04496349 | Ascentage Pharma Group Inc. | Phase 2 | Recruiting | 2026-05-31Estimated |
| Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsNCT04504942 | CytoDyn, Inc. | Phase 2 | Completed | 2021-11-07Actual |
| A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaNCT04508621 | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 2021-11-01Actual |
| Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantNCT04511130 | MRKR | Phase 2 | Terminated | 2024-03-01Actual |
| Losmapimod Safety and Efficacy in COVID-19NCT04511819 | Fulcrum Therapeutics | Phase 3 | Terminated | 2021-03-31Actual |
| An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's DiseaseNCT04514367 | ANNX | Phase 2 | Completed | 2022-08-29Actual |
| A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal DisordersNCT04516278 | OTLK | Phase 3 | Completed | 2021-02-10Actual |
| VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia CongenitaNCT04520750 | PVLA | Phase 3 | Completed | 2021-06-30Actual |
| A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With AcromegalyNCT04522180 | IONS | Phase 2 | Completed | 2022-07-15Actual |
| Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiNCT04524390 | MIRM | Phase 2 | Completed | 2023-11-07Actual |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)NCT04524403 | Corcept Therapeutics | Phase 2 | Completed | 2022-07-29Actual |
Trial details
- Registry ID
- NCT04439071
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04442022
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04445688
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04445987
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04446117
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04447469
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04452591
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04455633
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04457336
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04466891
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04467840
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04475432
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04476017
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04480840
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04485104
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04488419
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04491006
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04492163
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04495153
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04496349
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04504942
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04508621
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04511130
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04511819
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04514367
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04516278
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04520750
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04522180
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04524390
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04524403
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.